WCN23-0666 EFFICACY AND SAFETY OF DAPAGLIFLOZIN IN PATIENTS WITH CHRONIC KIDNEY DISEASE ACROSS THE SPECTRUM OF FRAILTY

Frail patients are perceived to benefit less from healthcare services and are less likely to receive medical and surgical interventions than non-frail patients. In this study, we examined the safety and efficacy of dapagliflozin by levels of frailty in patients with chronic kidney disease (CKD) enrolled in the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) trial (NCT03036150).